Funding for this research was provided by:
Eli Lilly and Company (N/A)
Text and Data Mining valid from 2018-04-03
Received: 27 July 2017
Accepted: 22 February 2018
First Online: 3 April 2018
Ethics approval and consent to participate
: Ethical review board approval of the GERAS study was obtained in each country according to individual country regulations, as follows: France—Commission Nationale de l’Informatique et des Libertés (CNIL) (reference EGY/DP/AR104863); Germany—Philipps University, Marburg, Fachbereich Medizin, Dekanat/Ethikkommission (reference 105/10); UK—NHS National Research Ethics Service, South West 5 REC (reference 10/H0107/43) and Scotland A Research Ethics Committee (reference number 10/MRE00/63). The patient (or their legal representative) and caregiver were both required to provide written informed consent prior to enrolment.For the EXPEDITION trials, the research protocol was approved by the ethical review board at each study site participating in that trial. Written informed consent for study participation was provided by the study subject or a legally authorised representative.
: Not applicable for EXPEDITION or GERAS studies.
: All authors are employees of Eli Lilly and Company, except Dr David Henley and Dr Gopalan Sethuraman who were employees of Eli Lilly and Company at the time the study was conducted and when the paper was drafted and finalised. No non-financial conflicts of interest exist for any of the authors.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.